Literature DB >> 24887380

Lomustine use in combination with etoposide, cytarabine and melphalan in a brief conditioning regimen for auto-HSCT in patients with lymphoma: the optimal dose.

K B dos Santos1, L J Costa2, A Atalla3, J Pereira4, A E Hallack-Neto3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24887380     DOI： 10.1038/bmt.2014.121

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  7 in total

1.  LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre.

Authors:  J B Perz; C Giles; R Szydlo; D O'Shea; J Sanz; A Chaidos; S Wagner; J Davis; S Loaiza; D Marin; J Apperley; E Olavarria; A Rahemtulla; I Lampert; K Naresh; D Samson; D MacDonald; E J Kanfer
Journal:  Bone Marrow Transplant       Date:  2006-11-20       Impact factor: 5.483

2.  BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.

Authors:  Giuseppe Visani; Lara Malerba; Pietro Maria Stefani; Saveria Capria; Piero Galieni; Francesco Gaudio; Giorgina Specchia; Giovanna Meloni; Filippo Gherlinzoni; Claudio Giardini; Sadia Falcioni; Francesca Cuberli; Marco Gobbi; Barbara Sarina; Armando Santoro; Felicetto Ferrara; Marco Rocchi; Enrique M Ocio; Maria Dolores Caballero; Alessandro Isidori
Journal:  Blood       Date:  2011-08-03       Impact factor: 22.113

3.  Modified BEAM conditioning regimen in patients with Hodgkin and non-Hodgkin lymphomas.

Authors:  Abrahão Elias Hallack Neto; Kelli Borges dos Santos; Angelo Atalla
Journal:  Exp Clin Transplant       Date:  2012-12       Impact factor: 0.945

4.  Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol.

Authors:  Mani Ramzi; Mohsen Mohamadian; Reza Vojdani; Mehdi Dehghani; Habib Nourani; Maryam Zakerinia; Hoorvash Haghighinejad
Journal:  Exp Clin Transplant       Date:  2012-04       Impact factor: 0.945

5.  Infection profile of patients undergoing autologous bone marrow transplantation in a Brazilian institution.

Authors:  Kelli Borges Santos; Abrahão Elias Hallack Neto; Girlene Alves Silva; Angelo Atalla; Marcus Matta Abreu; Luiz Cláudio Ribeiro
Journal:  Sao Paulo Med J       Date:  2012       Impact factor: 1.044

6.  Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease.

Authors:  M J Stuart; N S Chao; S J Horning; R M Wong; R S Negrin; L J Johnston; J A Shizuru; G D Long; K G Blume; K E Stockerl-Goldstein
Journal:  Biol Blood Marrow Transplant       Date:  2001       Impact factor: 5.742

7.  A new preparatory regimen for autologous bone marrow transplantation for patients with lymphoma.

Authors:  N J Chao; H Kastrissios; G D Long; R S Negrin; S J Horning; R M Wong; T F Blaschke; K G Blume
Journal:  Cancer       Date:  1995-03-15       Impact factor: 6.860
  7 in total
  1 in total

1.  Infectious diarrhea in autologous stem cell transplantation: high prevalence of coccidia in a South American center.

Authors:  Marcelo Dias de Castro; Julio Maria Chebli; Luciano José Costa; Katia Regina Lopes Alves; Angelo Atalla; Abrahao E Hallack Neto
Journal:  Hematol Transfus Cell Ther       Date:  2018-02-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.